The PDUFA date for CARDAMYST™ is set for March 27, 2025, indicating a lengthy approval timeline that could delay commercialization and revenue generation for the company. The reliance on the FDA's ...
MONTREAL and CHARLOTTE, N.C., Nov. 11, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced positive Phase 2 data that show etripamil nasal spray resulted in rapid and ...
- Self-administration of etripamil in patients experiencing AFib-RVR episodes resulted in a substantial reduction in ventricular rate which was sustained over 60 minutes - Data featured in an oral ...
New Drug Application submitted to the U.S. Food and Drug Administration for CARDAMYST ™, the conditionally approved brand name for etripamil nasal spray, for patients with PSVT Positive Phase 2 data ...
PDUFA Target Date of December 13, 2025 for CARDAMYST™ (etripamil) Nasal Spray in Paroxysmal Supraventricular Tachycardia (PSVT) Promotional Launch Plans Set with Quick-Start Capability Upon Potential ...
MONTREAL and CHARLOTTE, N.C., May 8, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative ...
CARDAMYST nasal spray is a novel and rapid-acting calcium channel blocker delivered when needed to treat often highly symptomatic and unpredictable episodes of PSVT. With CARDAMYST, adults with PSVT ...
Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate (p 0.0001) ...
"Data from this unplanned analysis represent the first direct clinical evidence of the impact of etripamil on heart rate in patients experiencing an event of AFib-RVR," said Joseph Oliveto, President ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback